{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Vineet Laboratories Ltd
Vineet Laboratories Ltd Downgraded to Strong Sell Amidst Weak Fundamentals and Technical Setbacks
Vineet Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 10 March 2026, reflecting deteriorating technical indicators and weak fundamental performance. The downgrade is driven by a combination of sideways technical trends, poor financial results, unfavourable valuation metrics, and declining quality scores, signalling heightened risk for investors in this Pharmaceuticals & Biotechnology stock.
Vineet Laboratories Ltd is Rated Sell
Vineet Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into the company’s performance and outlook.
Vineet Laboratories Ltd is Rated Sell
Vineet Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 February 2026, providing investors with the latest insights into the company’s performance and outlook.
When is the next results date for Vineet Laboratories Ltd?
The next results date for Vineet Laboratories Ltd is 14 February 2026.
Vineet Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Technical Signals
Vineet Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 6 February 2026, reflecting deteriorating fundamentals, challenging valuation metrics, a negative financial trend, and mixed technical signals. The pharmaceutical company’s recent performance and outlook have raised concerns among analysts, prompting a reassessment of its investment appeal.
Vineet Laboratories Ltd Upgraded to Sell on Improved Technicals Despite Weak Fundamentals
Vineet Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 February 2026, driven primarily by a marked improvement in technical indicators. However, the company continues to face significant challenges on the fundamental and financial fronts, with deteriorating profitability and weak long-term growth prospects weighing heavily on investor sentiment.
Vineet Laboratories Ltd is Rated Strong Sell
Vineet Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 January 2026, providing investors with the latest insights into its performance and outlook.
Why is Vineet Laboratories Ltd falling/rising?
On 02-Jan, Vineet Laboratories Ltd witnessed a notable decline in its share price, closing at ₹34.28, down ₹1.49 or 4.17% from the previous session. This drop reflects a continuation of a downward trend influenced by deteriorating financial performance and waning promoter confidence.
Vineet Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Mixed Technicals
Vineet Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 29 Dec 2025. This shift reflects deteriorating financial fundamentals, subdued valuation appeal, and a complex technical outlook, despite some mildly bullish signals. The company’s recent performance and market trends highlight significant challenges ahead for investors.
Vineet Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals
Vineet Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. Despite ongoing challenges in profitability and sales, recent technical trends suggest a more optimistic market outlook, prompting a reassessment of the company’s investment profile.
Vineet Laborator Sees Revision in Market Assessment Amid Challenging Fundamentals
Vineet Laborator, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and operational metrics. The recent shift in evaluation metrics highlights concerns across quality, valuation, financial trends, and technical outlook, underscoring the complexities facing the company in a competitive industry environment.
Why is Vineet Laborator falling/rising?
As of 18-Nov, Vineet Laboratories Ltd's stock price is Rs 41.23, down 2.53%, and has declined 10.27% over the last four days. The company faces significant challenges, including negative returns over the past year and weak fundamentals, contributing to a lack of investor confidence.
Why is Vineet Laborator falling/rising?
As of 14-Nov, Vineet Laboratories Ltd's stock price is declining at 43.43, down 0.89%, with a total return of -5.48% over the last two days. The stock has significantly underperformed year-to-date and over the past year compared to the Sensex, indicating a challenging environment.
How has been the historical performance of Vineet Laborator?
Vineet Laborator has experienced a significant decline in financial performance, with net sales dropping from 243.48 Cr in March 2021 to 75.00 Cr in March 2025, resulting in a loss of 20.19 Cr after tax. Despite a slight recovery in cash flow from operating activities, the overall financial position remains weak.
Are Vineet Laborator latest results good or bad?
Vineet Laboratories' latest results show a mixed picture: while the company achieved a net profit of ₹0.40 crores, a turnaround from a loss, it faces declining revenues and significant structural challenges, raising concerns about its financial health and future prospects.
Vineet Laboratories Q2 FY26: Profitability Returns But Revenue Concerns Persist
Vineet Laboratories Ltd., a micro-cap pharmaceutical intermediates manufacturer, posted a net profit of ₹0.40 crores in Q2 FY26, marking a dramatic turnaround from the ₹0.87 crores loss recorded in the previous quarter. However, the profitability recovery was overshadowed by persistent revenue challenges, with net sales declining 8.12% year-on-year to ₹17.42 crores, raising questions about the sustainability of this turnaround.
How has been the historical performance of Vineet Laborator?
Vineet Laborator has experienced significant declines in revenue and profitability, with net sales dropping from 243.48 Cr in Mar'21 to 75.00 Cr in Mar'25, resulting in negative earnings and cash flow in the latest fiscal year. Total assets and liabilities have also decreased, reflecting a challenging financial period for the company.
Vineet Laboratories Faces Financial Struggles Amid Mixed Technical Trends
Vineet Laboratories, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment due to shifts in technical indicators. Despite some bullish trends, the company faces significant financial challenges, including declining net sales and profit, low inventory turnover, and weak long-term fundamentals, raising concerns about its future.
Why is Vineet Laborator falling/rising?
As of 28-Oct, Vineet Laboratories Ltd is currently priced at 45.65, reflecting a 1.69% increase and strong recent performance with an 8.43% gain over two days. Despite short-term gains, the stock has a year-to-date decline of 26.78%, contrasting with the Sensex's increase of 8.30%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
